Advertisement

Picture EBD Group BIO-Europe 2021 Digital BEU2021 650x80
Document › Details

Satorius AG. (1/6/21). "Press Release: Sartorius to Acquire Novasep’s Chromatography Process Equipment Division". Göttingen.

Organisations Organisation Sartorius Stedim Biotech S.A. (SSB)
  Group Sartorius (Group)
  Organisation 2 Novasep S.A.
  Group Novasep (Group)
Products Product chromatography
  Product 2 laboratory equipment and instruments
Persons Person Fáber, René (Sartorius 202010 Head of Bioprocess Solutions Division)
  Person 2 Spagnol, Michel (Novasep 201306– CEO before Shasun + Rhodia)
     


> Proposed transaction builds on both companies’ strategic R&D partnership

> Strengthens Sartorius position in downstream bioprocessing


The life science company Sartorius today announced it has entered into an agreement through its subgroup Sartorius Stedim Biotech to acquire the chromatography process equipment division of Novasep. The parties agreed not to disclose the purchase price until the necessary regulatory approvals have been obtained. Novasep’s division expects to generate sales revenue of approximately 37 million euros in 2020 at double-digit profit margins and employs approximately 100 people, the majority of whom work at its Pompey site in northern France and some in the USA, China and India. The proposed transaction is subject to antitrust approvals and the information and consultation of Novasep’s works council and is expected to close during the first half of 2021.

Novasep’s chromatography unit comprises resin-based batch and intensified chromatography systems, and primarily focuses on high-pressure, multi-use applications for smaller molecules, such as oligonucleotides, peptides and insulin. Since 2018, Novasep and Sartorius have been collaborating in the joint development of an optimized systemfor a membrane-based, low-pressure chromatography that processes larger molecules more productively and that will be launched soon.

“I am pleased that we will intensify our successful collaboration with the Novasep team, soon to be under the Sartorius roof,” said Dr. René Fáber, Head of the Sartorius Bioprocess Solutions Division and Executive Board member. “The Novasep portfolio will perfectly complement our existing chromatography offering and allow us to provide customers with more options for their manufacturing processes. Efficient DSP has remained a challenge in our industry for years, and Sartorius is committed to helping accelerate and simplify this crucial step so that new drugs can be manufactured much more efficiently.”

“This deal marks one of the first steps in our Rise-2 strategic program to focus the group towards our core business” said Dr. Michel Spagnol, President & CEO of Novasep. “We are delighted to strengthen our relationship with the Sartorius team and believe it will be a great opportunity for the chromatography equipment business to fully deliver its potential and accelerate its growth under this new ownership.”


This press release contains forward-looking statements about the future development of the Sartorius Group. Forward-looking statements are subject to known and unknown risks, uncertainties and other factors that could cause actual results to differ materially from those expressed or implied by such statements. Sartorius assumes no liability for updating such statements in light of new information or future events. This is a translation of the original German-language press release. Sartorius shall not assume any liability for the correctness of this translation. The original German press release is the legally binding version.



About Sartorius

The Sartorius Group is a leading international partner of life science research and the biopharmaceutical industry. With innovative laboratory instruments and consumables, the Group’s Lab Products & Services Division concentrates on serving the needs of laboratories performing research and quality control at pharma and biopharma companies and those of academic research institutes. The Bioprocess Solutions Division with its broad product portfolio focusing on single-use solutions helps customers to manufacture biotech medications and vaccines safely and efficiently. The Group has been annually growing by double digits on average and has been regularly expanding its portfolio by acquisitions of complementary technologies. In fiscal 2019, the company earned sales revenue of some 1.83 billion euros. At the end of 2019, more than 9,000 people were employed at the Group’s approximately 60 manufacturing and sales sites, serving customers around the globe.


About Novasep

Novasep is a global provider of cost-effective and sustainable manufacturing solutions for life sciences molecules and fine chemicals. Novasep’s unique offering includes process development services, purification equipment and turnkey processes, contract manufacturing services and complex active molecules to serve pharmaceutical, biopharmaceutical, fine chemical, food and functional ingredients, as well as fermentation and chemical commodities industries. http://www.novasep.com


Sartorius contact

Petra Kirchhoff
Head of Corporate Communicationsand Investor Relations
+49 (0)551.308.1686
petra.kirchhoff@sartorius.com
www.sartorius.com


Novasep contacts

Brice Roquet / Laure Saloin
Communication Project Managers
+33 7 77 94 37 55 / +33 7 77 94 37 52
brice.roquet@novasep.com / laure.saloin@novasep.com


Follow Sartorius onTwitter@Sartorius_Group and onLinkedIn

   
Record changed: 2021-07-30

Advertisement

Picture [iito] Plain Stupid Simple 650x80px

More documents for Sartorius (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture Demy-Colton BioFuture 2021 NYC E Hand 650x300px




» top